Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of CZ48 in Solid Tumors and Lymphoma
NCT02575638Phase 1Unknown
- Sponsor
- Cao Pharmaceuticals Inc.
- Start
- Jul 2008
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camptothecin-20-O-propionate in solid tumor and malignant lymphoma, sponsored by Cao Pharmaceuticals Inc. Primary endpoint: Dose Limiting Toxicities at 4 weeks. Status: unknown.
02
Drugs
camptothecin-20-O-propionate
03
Conditions
solid tumormalignant lymphoma
Beyond the preview
Go deeper on NCT02575638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02575638.